Lung cancer is the leading cause of cancer deaths globally, and it is often detected too late, with more than half of cases metastasizing by the time they are first diagnosed1… but there is hope.
With patients at the heart of everything we do, The Lung Cancer Initiative (LCI) at Johnson & Johnson was formed in 2018 to unleash the full potential of lung cancer science to help change the trajectory of this complex disease.
As an R&D engine, the LCI takes a multidisciplinary approach in bringing together the unparalleled expertise, technology, scale and reach across Johnson & Johnson within its Pharmaceutical, Medical Device and Consumer Health sectors, and works with collaborators worldwide to advance innovations that aim to create more effective and personalized treatments for lung cancer with the goal to improve patient outcomes.
1 GLOBOCAN 2020: SEER 18 2010–2016; SEER Cancer Stat Facts